In our study herein, we demonstrate that both SAM-cooperative (e.g., pemrametostat) and SAM-competitive (e.g., JNJ-64619178) PRMT5i suppress growth of both ER+/RB-deficient and RB-competent breast cancers in vitro and/or in vivo. This evidence concerns the gene ESR1 and breast carcinoma.